Morgan Stanley: Maintains "Underperform" rating for STELLA HOLDINGS (01836), target price raised to HKD 12.
Morgan Stanley raised its net profit forecast for Nine Express Holdings (01836) for the fiscal year 2024-25 by 4.7% and 8%.
Morgan Stanley released a research report stating that STELLA HOLDINGS (01836) saw a 3% increase in freight volume in the fourth quarter year-on-year, but due to unfavorable product mix and falling raw material prices, the average price dropped by 3.1%. The group's revenue fell by 1.1% year-on-year. The bank raised the group's net profit forecast for the fiscal year 2024 to 2025 by 4.7% and 8%, and raised the target price by 9% from HK$11 to HK$12, maintaining an "underperform" rating.
The bank cited NineX management as saying that due to weakening orders from luxury brands and a shift towards lower-priced products, the group is expected to achieve a 5% increase in sales volume this year, while the average price is expected to drop by 1 to 2%. The target operating profit margin is expected to expand year-on-year. However, Morgan Stanley remains cautious about this target because there will be a period of ramp-up after the new production capacity comes online to achieve full utilization, and management expects worker wages to increase by over 5% year-on-year.
Related Articles

Microsoft Corporation (MSFT.US) and NVIDIA Corporation (NVDA.US) have announced their investment of up to $15 billion in Anthropic. "Circular AI investment" has raised concerns of a bubble.
US Stock Market Move | Merck & Co., Inc. (MRK.US) rose more than 4% as Winrevair succeeded in a new mid-stage trial for lung indications.

US Stock Market Move | iQIYI, Inc. Sponsored ADR Class A (IQ.US) rose more than 4%, with overseas business continuing to maintain high-speed growth.
Microsoft Corporation (MSFT.US) and NVIDIA Corporation (NVDA.US) have announced their investment of up to $15 billion in Anthropic. "Circular AI investment" has raised concerns of a bubble.

US Stock Market Move | Merck & Co., Inc. (MRK.US) rose more than 4% as Winrevair succeeded in a new mid-stage trial for lung indications.
US Stock Market Move | iQIYI, Inc. Sponsored ADR Class A (IQ.US) rose more than 4%, with overseas business continuing to maintain high-speed growth.

RECOMMEND

Tech Stocks, Crypto, and Gold Slump; U.S. Equities Break Key Support Amid Broad-based Sell-off
18/11/2025

Goldman Sachs’ Ten-year Investment Outlook: Artificial Intelligence and Emerging Markets As Core Growth Engines
18/11/2025

Consensus On Multiple Outcomes, Easing Trade Tensions, China–Germany High-level Financial Dialogue Convened In Beijing
18/11/2025


